"Working with Fosun Pharma to Advance Approval and Commercialization"

Samjin Pharmaceutical said on November 18, regarding the global Phase 3 results for AR1001, AriBio's oral Alzheimer's disease drug candidate,  "We consider the trial results a success and plan to work with AriBio to accelerate the drug's approval and commercialization." Samjin Pharmaceutical holds the rights to manufacture and exclusively sell AR1001 in South Korea.


Samjin Pharmaceutical officials are holding a meeting. Samjin Pharmaceutical

Samjin Pharmaceutical officials are holding a meeting. Samjin Pharmaceutical

View original image

AriBio announced the topline results of the global Phase 3 POLARIS-AD trial of AR1001 the previous day at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, United States. The trial involved 1,535 patients with early Alzheimer's disease in 13 countries, who received either 30 mg of AR1001 or a placebo once daily for 52 weeks. AriBio said the trial was designed, in consultation with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to meet its primary objective if statistical significance was achieved in either the overall patient population or the monotherapy group, which did not take existing symptom-relief medications.


According to AriBio, among the 604 patients in the prespecified monotherapy group, AR1001 slowed worsening on the primary endpoint, the Clinical Dementia Rating-Sum of Boxes (CDR-SB), by 31% compared with placebo. The difference in scores between the two groups was 0.44 points, which was statistically significant. AR1001 also showed a significant 0.7-point difference from placebo on the Mini-Mental State Examination (MMSE), a secondary endpoint.


Kim Sangjin, president of Samjin Pharmaceutical, who attended the presentation in the United States, said, "We believe AR1001 has succeeded in its global Phase 3 trial," adding, "We also agreed with the CEO of Fosun Pharma to coordinate our efforts to accelerate commercialization." Fosun Pharma previously signed a global exclusive licensing agreement with AriBio.



President Kim cited the Phase 3 trial design, which incorporated the Phase 2 results, as a factor behind the achievement. "We incorporated into the Phase 3 protocol design from the outset the finding from Phase 2 that the treatment was more effective in patients who were not taking symptom-relief medications concurrently," he explained. He added, "During the clinical trial approval process with the FDA and EMA, we set strict success criteria for both the overall patient population and the monotherapy group, and agreed that the primary objective would be met if either group satisfied the criteria."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing